Mural Oncology (MURA) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

MURA Mural Oncology

Watchlist

3.470
+0.030+0.87%

Close Jan 7 16:00 ET

3.640
+0.170+4.90%

Post 20:01 ET

59.20MMarket Cap-0.38P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Mural Oncology Grants Stock Options and Restricted Stock Units to New Employees as Part of 2024 Inducement Plan
Quiver QuantitativeDec 3, 2024 16:21 ET
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswireDec 3, 2024 16:15 ET
Express News | Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersDec 3, 2024 16:15 ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
BenzingaNov 25, 2024 16:05 ET
Mural Oncology Reports Positive ARTISTRY-1 Trial Results for Nemvaleukin in Advanced Solid Tumors, Including Platinum-Resistant Ovarian Cancer
Quiver QuantitativeNov 20, 2024 16:21 ET
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in Its ARTISTRY-1 Clinical Trial of Nemvaleukin, Its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
GlobeNewswireNov 20, 2024 16:15 ET

Comments

Teddy123

Nov 20, 2024 17:49

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for Im

$Mural Oncology (MURA.US)$
Mural Oncology's Cancer Drug Shows 33% Response Rate in Melanoma Trial Data | MURA Stock News

Jaguar8

Nov 20, 2024 15:19

NEWS

$Mural Oncology (MURA.US)$
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Mural Oncology has published promising clinical data from its completed ARTISTRY-1 phase 1/2 trial of nemvaleukin, showing positive antitumor activity in both monotherapy and combination therapy with pembrolizumab.
The trial, involving 286 patient...

Jaguar8

Nov 7, 2024 15:16

NEWS

$Mural Oncology (MURA.US)$
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Mural Oncology presented clinical and preclinical data at the 39th SITC Annual Meeting. The ARTISTRY-3 trial showed that less frequent IV dosing of nemvaleukin demonstrated tumor site-specific immune activation in ovarian cancer and mucosal melanoma patients. Preclinical data from IL-18 variants showed durable immune ...

Jaguar8

Nov 4, 2024 13:47

NEWS 13G

$Mural Oncology (MURA.US)$
Mural Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(4.90%)

Jaguar8

May 23, 2024 16:03

$Mural Oncology (MURA.US)$
NEWS
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizu...

Heat List

Overall

No Data